Tumor cell survival and cell-cycle machinery

Tumor cell survival and cell-cycle machinery refers to the integrated network of proteins and signaling pathways that govern the division and persistence of cancer cells. The cell-cycle machinery primarily consists of cyclin-dependent kinases (CDKs) and cyclins that regulate the transition between phases of the cell cycle, often becoming hyperactive in tumors to drive rapid proliferation (Hanahan & Weinberg, 2011, Cell). Concurrently, tumor survival is maintained through the upregulation of anti-apoptotic proteins, such as Bcl-2, which allow cells to evade death signals even under conditions of genomic instability or therapeutic stress (Adams & Cory, 2007, Oncogene). Targeting these mechanisms is a cornerstone of modern oncology, with drugs like CDK4/6 inhibitors and Bcl-2 antagonists designed to halt cell division or directly induce apoptosis (Sherr, 1996, Science). Because this term encompasses a wide array of distinct molecular targets rather than a single entity, it is classified as a pathway or biological process rather than a specific therapeutic target molecule. Therapeutic strategies often involve combination treatments to simultaneously inhibit proliferation and promote cell death. Biomarkers such as Ki-67 and specific protein expressions are used to monitor the activity of these pathways in clinical settings.

Other names

Cell cycle regulatorsApoptosis pathwaysSurvival signalingProliferation machinery

Inhibition of cyclin-dependent kinases (CDKs) to induce cell cycle arrest and antagonism of anti-apoptotic proteins (e.g., Bcl-2) to trigger programmed cell death.